Skip to main content

Table 2 mRNA biomarkers and gene mutation status

From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Biomarkers and mutations N (%) Median RQ Interquartile range (IQR)
AREG 168 39.9 38.7-40.9
EREG 160 36.4 34.7-37.9
EGF 167 29.3 27.9-33.6
TGFa 162 37.1 36.2-37.9
EGFR 168 38.3 37.7-39.2
KRAS N=205    
All mutations 72 (31.9%)   
G12 45 (20.0%)   
G13 16 (7.0%)   
Q61 4 (1.7%)   
A146 7 (3.1%)   
Wild type 133 (58.8%)   
Missing 21 (9.3%)   
NRAS N=159    
All mutations 7 (3.1%)   
Q61 5 (2.2%)   
G12 2 (0.9%)   
Wild type 152 (67.3%)   
Missing 67 (29.6%)   
BRAF N=220    
V600E 6 (2.6%)   
Wild type 214 (94.7%)   
Missing 6 (2.6%)   
PIK3CA N=220    
All mutations 37 (16.4%)   
Exon 9 20 (8.8%)   
Exon 20 5 (2.2%)   
Other 12 (5.3%)   
Wild type 183 (81.0%)   
Missing 6 (2.6%)